Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BSE safety

This article was originally published in The Tan Sheet

Executive Summary

Pharmaca Integrative Pharmacy announces removal of dietary supplements containing bovine-derived brain, skull, eye and nerve materials from shelves Feb. 24 as a result of bovine spongiform encephalopathy (BSE, or mad cow disease) safety concerns. Removal affects six "hormonal cognitive and support" products primarily sold to naturopathic practitioners. Pharmaca's action follows FDA's recent announcement of intention to ban a range of bovine-derived materials from food products, including dietary supplements (1"The Tan Sheet" Feb. 2, 2004, p. 9)...

You may also be interested in...

BSE Interim Final Rules To Ban Materials In Certain Supplements

FDA and HHS will publish two interim final rules intended to ban certain bovine-derived materials from food products, including dietary supplements, in order to prevent the spread of bovine spongiform encephalopathy (BSE, also known as "mad cow disease")

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts